Convidecia (Trade Mark) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Solution for Injection
Category: Drug Info
Specifications
Details
Manufacturer
CanSino Biologics Inc(CHINA)
Registraction Number
MAL21066050AZ
Contents:
- Active Ingredient: Each 0.5 mL contains ≥ 4×10¹⁰ viral particles of replication-defective recombinant human type 5 Adenovirus expressing the S protein of SARS-CoV-2.
- Form: Sterile liquid injection in a 2 mL glass vial, with each vial containing a single dose of 0.5 mL.
- Usage: For active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 18 years and older.
- Booster Dose: A booster dose (0.5 mL) may be administered at least 3-6 months after the first dose, based on vaccine effectiveness data and safety considerations.
- Administration: Injected as a single dose for intramuscular injection in the deltoid muscle of the upper arm.
- Preparation: Use a disposable medical-grade syringe to extract the liquid from the vial. Ensure to remove any air bubbles before injection.
- Storage: Follow the storage guidelines provided with the vaccine to ensure its efficacy.
- Precautions: Do not use if the vial or syringe is cracked, if there are visible particles, or if the expiry date has passed.
View more about Convidecia (Trade Mark) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Solution for Injection on main site